From The Motley Fool · Motley Fool Transcribing · · 2m
Bristol-Myers Squibb Q3 2026 Earnings Report
Bristol-Myers Squibb reports 7% revenue growth with strong pipeline progress and full-year guidance upgrades.
In brief
Bristol-Myers Squibb reports 7% revenue growth with strong pipeline progress and full-year guidance upgrades. Bristol-Myers Squibb reported 7% year-over-year revenue growth to $13.1 billion in Q3 2026, with 8 growth portfolio medicines annualizing over $1 billion each. Originally reported by The Motley Fool.
Q3 Revenue Growth
Bristol-Myers Squibb reported 7% year-over-year revenue growth to $13.1 billion in Q3 2026.
Growth Portfolio Expansion
Growth portfolio revenue increased 12% to $7.7 billion driven by Reblozyl, Breyanzi, and Opdualag.
Eliquis Performance
Eliquis revenue reached $4.7 billion, up 26% from favorable pricing and strong market share gains.
Opdivo Transition
Opdivo revenue decreased 6% as 17% of patients switched to subcutaneous Qvantig formulation.
Reblozyl Growth
Reblozyl revenue grew 22% to $750 million with increased demand in first-line myelodysplastic syndromes.
Breyanzi Surge
Breyanzi revenue increased 48% to $526 million due to strong global demand.
Camzyos Expansion
Camzyos revenue grew 42% to $420 million with deeper community market penetration.
Sotyktu Growth
Sotyktu revenue increased 26% with new psoriatic arthritis indication approval.
Cobenfy Performance
Cobenfy revenue grew 33% to $57 million despite inventory drawdown impacts.
Acquired IPRD Charges
Company recorded $1.6 billion in acquired in-process research and development charges.
Full-Year Guidance
Raised full-year revenue guidance to $49.75 billion to $50.25 billion with non-GAAP EPS of $6.35 to $6.55.
Manufacturing Investments
Investing $2.3 billion in Houston campus and $173 million in Indiana radiopharmaceutical expansion.
Productivity Initiative
Targeting $2 billion in efficiency savings by end of 2027 through operational improvements.
Eliquis LOE Impact
Anticipating $1.5 billion to $2 billion revenue step down for Eliquis in 2027 due to European patent expiration.
Symvexis Launch
Symvexis, first approved CELMoD, achieved positive early launch feedback with strong Phase 3 data.
Pipeline Progress
Multiple Phase 3 results expected for Milvexian in stroke prevention and Sotyktu in lupus by year end.
The big picture
Bristol-Myers Squibb reported 7% year-over-year revenue growth to $13.1 billion in Q3 2026, with 8 growth portfolio medicines annualizing over $1 billion each.
